Skip to main content

Advertisement

SpringerLink
Log in

Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus

  • Clinical Experience
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To evaluate the efficacy of HangAm-Plus (HAP) on stage IV metastatic gastric cancer by analyzing the treated patients’ overall survival outcome.

Methods

Following the study eligibility, overall survival and one year survival rate of 44 stage IV metastatic gastric cancer patients who visited East-West Cancer Center (EWCC) were analyzed. The study consisted of two arms: HAP treatment only (n=18) and combined treatment of concurrent conventional chemotherapy and HAP (n=26). Patient characteristics by gender, age, surgical intervention, Eastern Cooperative Oncology Group (ECOG) score, treatment duration (< 4 weeks or ⩾4 weeks), and lines of the chemotherapy received were assessed. Treatment related side effects were also assessed.

Results

The median survival of combined group was longer (10.0 months) than that of HAP group (5.1 months). One-year survival rate of combined treatment group and HAP group was 38.5%±9.5% and 33.3%±11.1%, respectively (P>0.05). One-year survival rate of those received more and less than 4-week treatment was 57.1%±18.7% and 8.3%±8.0%, respectively (P=0.001).

Conclusions

The study supports the safety and potential efficacy of HAP treatment in prevention of chemo-related side effects for stage IV metastatic gastric cancer treated with conventional chemotherapy. Further studies are needed to investigate and confirm the results before applying the treatment in clinical settings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shin HR, Won YJ, Jung KW, Park JG. 2001 annual report of the Korea Central Cancer Registry: base on registered data from 134 hospitals. Cancer Res Treat 2004;36:19–30.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Cancer Facts and Figures 2010. Seoul, Korea: National Cancer Center, Ministry of Health & Welfare: 2010.

    Google Scholar 

  3. Goekkurt E, Al-Batran SE, Mogck U, Pauligk C, Hartmann JT, Kramer M, et al. Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and doceetaxel (FLOT), a translational study of the Arbetisgemeinschaft Internistische Onkologie (AIO). Ann Oncol 2009;20:481–485.

    Article  CAS  PubMed  Google Scholar 

  4. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207–2212

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587–591.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37–41.

    Article  CAS  PubMed  Google Scholar 

  7. Hijioka S, Chin K, Seto Y, Yamamoto N, Hatake K. Eightyear survival after advanced gastric cancer treated with S-1 followed by surgery. World J Gastroenterol 2010;16:2824–2827.

    Article  PubMed  Google Scholar 

  8. Tham CK, Choo SP, Poon DY, Toh HC, Ong SY, Tan SH, et al. Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. World J Gastroenterol 2010;16:3709–3715.

    Article  CAS  PubMed  Google Scholar 

  9. Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Earle CC, Kulke MH, et al. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol 2009;20:475–480.

    Article  CAS  PubMed  Google Scholar 

  10. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813–3818.

    Article  CAS  PubMed  Google Scholar 

  11. Narahara H, Koizumi W, Hara T, Takagane A, Akiya T, Takagi M, et al. TS-1 Advanced Gastric Cancer (AGC) Clinical Trial Group. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215–221.

    Article  PubMed  Google Scholar 

  12. Takiuchi H, Goto M, Imamura H, Furukawa H, Imano M, Imamoto H, et al. Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302). Jpn J Clin Oncol 2008;38:176–181.

    Article  PubMed  Google Scholar 

  13. Koizumi W, Akiya T, Sato A, Yamaguchi K, Sakuyama T, Nakayama N, et al. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the Gastrointestinal Oncology Group of the Tokyo Cooperative Oncology Group, TCOG GC-0501 Trial. Jpn J Clin Oncol 2009;39:713–719.

    Article  PubMed  Google Scholar 

  14. Yildiz R, Kalender ME, Dane F, Sevinc A, Gumus M, Camci C, et al. Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum and fluoropyrimidine-based regimens. J Oncol Pharm Pract 2010;16:173–178.

    Article  CAS  PubMed  Google Scholar 

  15. Morita S, Baba H, Tsuburaya A, Takiuchi H, Matsui T, Maehara Y, et al. A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: trial for advanced stromach cancer (TASC). Jpn J Clin Oncol 2007;37:469–472.

    Article  PubMed  Google Scholar 

  16. Yoo HS, Lee YY, Song KC, Choi BL, Seo SH, Cho JH, et al. The effects of HangAmDan (HAD) on anti-metastasis and preventing relapses, administered to 69 cancer patients. Kor J Orient Int Med 2002;23:165–173.

    Google Scholar 

  17. Park JS, Yoo HS, Lee YW, Cho JH, Son CG, Cho CK. Wheel balance cancer therapy in the treatment of metastatic gastric carcinoma: a retrospective analysis of 62 patients. Kor J Orient Int Med 2007;28:531–543.

    Google Scholar 

  18. Choi BL, Kim HC, Song KC, Yoo HS, Cho JH, Lee YW, et al. Study on the toxicity of HangAm-Dan (HAD) in mice. J Kor Orient Oncol 2002;8:23–35.

    Google Scholar 

  19. Lee DE, Lee SY, Kim JS, Cho CK, Yoo HS, Choi SJ. Antitumor effect of Hang-Am-Dan (HAD) and its ingredients on Calu6 and MCF-7 human cancer cell lines. J Kor Oriental Med 2009;30:50–60.

    Google Scholar 

  20. Bang JY, Kim EY, Shim TK, Yoo HS, Lee YW, Kim YS, et al. Analysis of anti-angiogenic mechanism of HangAmDan-B (HAD-B), a Korean traditional medicine, using antibody microarray chip. Bio Chip J 2010;4:350–355.

    CAS  Google Scholar 

  21. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. Aug 9, 2006. Retrieved from: URL: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf

  22. Korea Central Cancer Registry, Ministry of Health and Welfare. 2009. Retrieved from: URL: http://www.cancer.go.kr/cms/statics/incidence/index.html

  23. Yun J, Lee J, Park SH, Park JO, Park YS, Lim HY, et al. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. Eur J Cancer 2010;46:885–891.

    Article  CAS  PubMed  Google Scholar 

  24. Wagner AD, Grothe W, Haerting J, Kleber G. Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903–2909.

    Article  CAS  PubMed  Google Scholar 

  25. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009;10:1063–1069.

    Article  CAS  PubMed  Google Scholar 

  26. Tanabe K, Suzuki T, Tokumoto N, Yamamoto H, Yoshida K, Ohdan H. Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis. World J Surg Oncol 2010;8(40):1–7.

    Google Scholar 

  27. Kang YK, Ryu MH, Yoo C, Chang HM, Yook JH, Oh ST, et al. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2011;67:1435–1443

    Article  CAS  PubMed  Google Scholar 

  28. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666–673.

    Article  PubMed  Google Scholar 

  29. Masashi F. Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). Int J Clin Oncol 2008;13:201–205.

    Article  Google Scholar 

  30. Cunningham D, Straling N, Rao S, Iverson T, Nicloson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36–46.

    Article  CAS  PubMed  Google Scholar 

  31. Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009;20:1529–1534.

    Article  CAS  PubMed  Google Scholar 

  32. van Cutsem E, Moiseysnko VM, Tjulandin S, Majlis A, Constenal M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991–4997.

    Article  PubMed  Google Scholar 

  33. Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 2008;8:148–157.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Kim BG, Oh SY, Kwon HC, Lee s, Lee DM, Kim SG, et al. A phase II study of irinotecan with biweekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (Modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer. Am J Clin Oncol 2010;33:246–250.

    CAS  PubMed  Google Scholar 

  35. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–697.

    Article  CAS  PubMed  Google Scholar 

  36. Zhuang SH, Xiu L, Elsayed YA. Overall survival: a gold standard in search of a surrogate: the value of progressionfree survival and time to progression as end points of drug efficacy. Cancer J 2009;15:395–400.

    Article  PubMed  Google Scholar 

  37. Park JS, Lee YW, Cho JH, Son CG, Cho CK, Yoo HS. A case regression of advanced gastric cancer by herbal medicine a retrospective case study with 8-year follow-up. Kor J Orient Int Med 2007;28:193–198.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. East-West Cancer Center, Dunsan Oriental Hospital of Daejeon University, 1136 Dunsandong Seogu Daejeon, 302-122, Soul, Korea

    Jae-Woo Park, Jeungwon Yoon, Chong-Kwan Cho, Yeon-Weol Lee & Hwa-Seung Yoo

Authors
  1. Jae-Woo Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeungwon Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chong-Kwan Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yeon-Weol Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hwa-Seung Yoo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hwa-Seung Yoo.

Additional information

These authors contributed equally to the manuscript

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, JW., Yoon, J., Cho, CK. et al. Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus. Chin. J. Integr. Med. 20, 49–55 (2014). https://doi.org/10.1007/s11655-012-1084-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-012-1084-0

Keywords

Search

Navigation